Summary
Large Degree of
Innovation in NSCLC Pipeline
The NSCLC pipeline
currently has 389 products in active development across all stages, but a stark
contrast between the mechanisms of action employed in the current market and
the pipeline is evident. Where the market comprises primarily ineffective chemotherapies
that target tubulin or DNA replication, the pipeline shows an incredibly
diverse range of therapies targeting multiple signaling pathways and molecules
integral to cancer development. This diversity is partially due to the presence
of 122 first-in-class products, which accounts for 38% of the overall pipeline
therapies that disclosed their target. In an industry, market and development
landscape that favors first-in-class over non-first-in-class development in
many ways, such as through faster approval or greater revenue, this finding has
strategic implications for a wide array of market participants, both large and
small. Despite a high attrition rate in NSCLC, first-in-class therapies that
reach the market have the potential to transform and improve the NSCLC
treatment landscape.
To Get Complete Report
With TOC: http://www.radiantinsights.com/research/frontier-pharma-non-small-cell-lung-cancer-identifying-and-commercializing-first-in-class-innovation
Alignment of
First-in-Class Molecular Target with Disease Causation
The method of
characterizing NSCLC tumors is currently shifting from the traditional
histology-based characterization to a more specific molecule-based method of
characterization. This has resulted in the identification of key oncogenic
mutations in NSCLC and has coincided with the rise of targeted pipeline
therapies, which are designed to target proteins in signaling pathways that are
frequently mutated, amplified or overexpressed in NSCLC. Aligning the molecular
target with disease-causing signaling pathways and frequently mutated pathways
therapies can benefit from reduced systemic cytotoxic effects while still
inhibiting tumor-promoting signaling. Therefore, targeted therapies often
display superior safety and efficacy to chemotherapies.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet
their market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment